To investigate the role of the increased B cell infiltration after STING agonist therapy, we conducted a survival study in mice with or without B-cell depletion by anti-CD19 and anti-B220 antibodies in HCA-1 murine HCC-bearing mice with underlying liver damage (Fig. 3D). Here, STING1 is linked to hepatocellular carcinoma.